StonvexLoading…
StonvexStonvexStonvexCore line items from XRAY's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $907.13M | $880.00M | $3.68B | $2.72B | $1.81B |
Operating Income | Not available | $-35.00M | $-422.00M | $-283.00M | $-65.00M |
Net Income | Not available | $-10.00M | $-598.00M | $-452.00M | $-25.00M |
EPS (Diluted) | $0.36 | $-0.05 | $-3.00 | $-2.27 | $-0.13 |
Total Assets | Not available | $5.23B | $5.43B | $5.65B | $6.07B |
Total Liabilities | Not available | $3.91B | $4.09B | $4.17B | $4.11B |
Cash & Equivalents | Not available | $190.00M | $326.00M | $363.00M | $359.00M |
Free Cash Flow OCF − CapEx | Not available | $-12.00M | $104.00M | $44.00M | $4.00M |
Shares Outstanding | Not available | 200.30M | 199.60M | 199.50M | 199.30M |